Key result
Short-term high-dose DAPT after rt-PA increases 90-day mRS 0-1 by ~43% vs standard therapy.
Why the study?
The study evaluated the efficacy and safety of short-term high-dose dual antiplatelet therapy following 0.6 mg/kg rt-PA intravenous thrombolysis in acute ischemic stroke.
Does short-term high-dose dual antiplatelet therapy after 0.6 mg/kg rt-PA improve functional outcomes and reduce stroke recurrence in patients with acute ischemic stroke?
RCT (n=208)
randomized
Does short-term high-dose dual antiplatelet therapy after 0.6 mg/kg rt-PA improve functional outcomes and reduce stroke recurrence in patients with acute ischemic stroke?
Absolute Event Rate: 50.5% vs 35.2%
p-value: p=< .05
Short-term high-dose dual antiplatelet therapy after 0.6 mg/kg rt-PA improves functional outcomes and reduces stroke recurrence and symptomatic intracranial hemorrhage compared to standard dose rt-PA and standard DAPT in acute ischemic stroke.
Authors
No takes yet. Share an insight, caveat, or question.
Supports short-term high-dose DAPT after 0.6 mg/kg rt-PA for better functional outcomes; extends randomized evidence on post-thrombolysis antiplatelet intensification.
Chen et al. (2023) conducted an RCT in acute ischemic stroke (AIS) (n=208). short-term high-dose dual antiplatelet therapy after 0.6 mg/kg rt-PA vs. 0.9 mg/kg rt-PA, 100 mg oral aspirin and 75 mg oral clopidogrel was evaluated on mRS score between 0 and 1 at 90 days (p=< .05). Short-term high-dose dual antiplatelet therapy after 0.6 mg/kg rt-PA increased the proportion of patients with mRS scores 0-1 at 90 days compared to standard therapy (50.5% vs 35.2%, P < .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: